

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 <a href="http://lobbyingdisclosure.house.gov">http://lobbyingdisclosure.house.gov</a>	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 <a href="http://www.senate.gov/lobby">http://www.senate.gov/lobby</a>
--	---

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

<b>1. Registrant Name</b> <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual AstraZeneca Pharmaceuticals LP			
<b>2. Address</b> Address1 <u>1800 CONCORD PIKE, P.O. BOX 15437</u> Address2 _____ City <u>WILMINGTON</u> State <u>DE</u> Zip Code <u>19850-5437</u> Country <u>USA</u>			
<b>3. Principal place of business (if different than line 2)</b> City _____ State _____ Zip Code _____ Country _____			
<b>4a. Contact Name</b> Ms. <u>Jamie Bell</u>	<b>b. Telephone Number</b> <u>2022467003</u>	<b>c. E-mail</b> <u>jamie.bell@astrazeneca.com</u>	<b>5. Senate ID#</b> <u>54073-12</u>
<b>7. Client Name</b> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality AstraZeneca Pharmaceuticals LP			<b>6. House ID#</b> <u>349750000</u>

**TYPE OF REPORT** 8. Year 2022 Q1 (1/1 - 3/31)  Q2 (4/1 - 6/30)  Q3 (7/1 - 9/30)  Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center"><b>12. Lobbying</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center"><b>13. Organizations</b></p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,170,000.00</u></p> <p><b>14. REPORTING</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Jamie Bell

Date 1/20/2023  
4:16:56 PM

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 483/S. 350 - Newborn Screening Saves Lives Act;  
 H.R. 1730/S. 670- Speeding Therapy Access Today Act  
 H.R. 1946, S. 1873. Cancer Moonshot Items related to the Administrations Cancer Moonshot initiative;  
 H.R. 5030/ S. 2706 DIVERSE Trials Act  
 HR 5376, Inflation Reduction Act reconciliation bill; Medicare price negotiation provision and Part D redesign; Preventative healthcare services and screenings; Issues related to preventative services and screenings for underrepresented communities  
 H.R. 6000 Cures 2.0 Act;  
 H.R. 6584 Diverse and Equitable Participation in Clinical Trials Act;  
 H.R. 6963 - Accelerated Approval Integrity Act;  
 H.R. 6996 Accelerating Access for Patients Act;  
 H.R.7667 - Food and Drug Amendments of 2022;  
 S. 1548, H.R. 3085/H.R. 7845. ENACT Act of 2021  
 S.4348 - FDASLA Act of 2022; General issues related to rare disease and orphan drugs; Reauthorization of the FDA User Fee Act; FDA modernization policy issues; Reauthorization of newborn screening programs; general issues related to health equity in rare disease and clinical trials; general issues related to diagnostics for patients with rare diseases; general issues related to pharmacy benefit managers (PBMs); general issues related to insurance coverage of specialty treatments  
 Issues related to clinical trial diversity  
 COVID-19; COVID-19 vaccine and therapy development  
 Climate, sustainability, and environment; Sustainability & Zero Carbon; Items related to environmental sustainability (including eliminating GHG emissions from pMDIs) and our Ambition Zero Carbon efforts.  
 E-Labeling  
 EVUSHELD  
 Issues related to repeal of the Medicaid AMP Cap.  
 Issues related to drug pricing, IRA  
 Drug Regulation, Approval, Clinical Trial Diversity and FDA User Fees;

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 3 Elijah E. Cummings Lower Drug Costs Now Act;  
 H.R. 19 - Lower Costs, More Cures Act;  
 H.R. 1946, S. 1873. Medicare Multi-Cancer Early Detection Screening Coverage;  
 H.R. 2617-accelerated approval in the Omnibus year end  
 H.R. 4065, S. 1971 (section 101), P.L. 117-328, H.R. 2617 Kidney disease screening, Expanding Medicare annual wellness benefit to include kidney disease screening.  
 H.R. 5260 - Reduced Costs and Continued Cures Act;  
 HR. 5376- Inflation Reduction Act; Build Back Better Act;  
 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure;  
 Preventative healthcare services and screenings Issues related to preventative services and screenings for underrepresented communities  
 IRA implementation, Pub. L. 117-169 Medicare Reform(s); Issues related to Medicare Part B and Part D pricing reform.  
 General issues related to patient access to rare disease therapies, Part B and Part D drugs; issues related to home infusion for Part B patients; Center for Medicare and Medicaid Innovation (CMMI) policy issues; value-based payment arrangements; efforts to improve coding, coverage, and access for rare disease therapies; issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies; general issues related to diagnostic reimbursement

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

H.R. 7559 E-labeling; and issues related to appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts (PI).  
 340B; Issues related to the 340B drug discount program

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

IP and Antitrust;  
 H.R. 2883- Stop Stalling Access to Affordable Medications  
 H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act  
 H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021  
 H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act  
 H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022  
 S. 1435- Affordable Prescriptions for Patients Act of 2021  
 S. 1425- Stop STALLING Act  
 Trade; Supply Chain and Manufacturing; H.R. 4521-United States Innovation and Competition Act of 2021, H. Rept. 117-235  
 Trade; Issues related to the World Trade Organization (WTO) waiver on Trade-related Aspects of Intellectual Property Rights (TRIPS) for COVID-19 vaccines

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Aaron	Hunter			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

H.R. 2623 – Cameron’s Law  
 H.R. 5376 - Build Back Better Act  
 Issues related to the Orphan Drug Tax Credit  
 Issues related to the deduction of research and development expenditures  
 Issues related to corporate and international tax reform  
 S. 749/H.R 1304 - American Innovation and Jobs Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 2617, Consolidated Appropriations Act, 2023  
 H.R. 7559 E-labeling; and issues related to appropriations hold on funding for a 2014 FDA rule that would provide electronic flexibilities related to package inserts (PI).  
 H.R. 8239/S. 4661, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act  
 H.R. 8295/S. 4659, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act,  
 H. Rept. 117-392, H. Rept. 117-403, H. Res. 1531. CTD, accelerated approval in the Omnibus year end, Consolidated Appropriations Act, 2023; P.L. 117-328.

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021  
 H.R. 2883- Stop Stalling Access to Affordable Medications  
 H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act  
 H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act  
 H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022  
 S. 1425- Stop STALLING Act  
 S. 1435- Affordable Prescriptions for Patients Act of 2021  
 TRIPS / IP Waiver  
 Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform, and Antitrust;

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Helen	Dwight			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

Climate, sustainability, and environment; Sustainability & Zero Carbon; Items related to environmental sustainability (including eliminating GHG emissions from pMDIs) and our Ambition Zero Carbon efforts.

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thad	Flood			<input type="checkbox"/>
Katie	Jones			<input type="checkbox"/>
Caroline	Quat			<input type="checkbox"/>
Aaron	Hunter			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Helen	Dwight			<input type="checkbox"/>
Sarah	Arbes			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

Drug Regulation, Approval, Clinical Trial Diversity and FDA User Fees; Cancer Moonshot Items related to the Administrations Cancer Moonshot initiative;  
 H.R. 6000-CURES Act 2.0  
 H.R. 5030/ S. 2706- DIVERSE Trials Act  
 H.R. 6584- DEPICT Act  
 H.R. 3085/S. 1548- ENACT Act of 2021  
 H.R. 7845- NIH Clinical Trial Diversity Act of 2022  
 H.R. 1946/, S. 1873- Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021

17. House(s) of Congress and Federal agencies  Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Aaron	Hunter			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

IP and Antitrust;  
H.R. 2883- Stop Stalling Access to Affordable Medications  
H.R. 2891- Preserve Access to Affordable Generics and Biosimilars Act  
H.R. 2873- Affordable Prescriptions for Patients Through Promoting Competition Act of 2021  
H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act  
H.R. 7032- Increasing Transparency in Generic Drug Applications Act of 2022  
S. 1435- Affordable Prescriptions for Patients Act of 2021  
S. 1425- Stop STALLING Act

17. House(s) of Congress and Federal agencies  Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Aaron	Hunter			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

21. Client new principal place of business (if different than line 20)

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_ Country \_\_\_\_\_

22. New General description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1	_____	_____	3	_____	_____
2	_____	_____	4	_____	_____

**ISSUE UPDATE**

24. General lobbying issue that no longer pertains

\_\_\_\_\_

